NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis → Dems have chosen Biden replacement? (From Paradigm Press) (Ad) Free RDY Stock Alerts $68.25 -1.05 (-1.52%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$68.17▼$69.1750-Day Range$68.25▼$77.2752-Week Range$53.12▼$77.72Volume216,782 shsAverage Volume246,298 shsMarket Capitalization$11.39 billionP/E Ratio16.94Dividend Yield0.60%Price Target$81.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Dr. Reddy's Laboratories alerts: Email Address Dr. Reddy's Laboratories MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside18.7% Upside$81.00 Price TargetShort InterestBearish0.52% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth-0.73%From $4.09 to $4.06 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.70 out of 5 starsMedical Sector847th out of 920 stocksPharmaceutical Preparations Industry394th out of 426 stocks 2.0 Analyst's Opinion Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageDr. Reddy's Laboratories has only been the subject of 1 research reports in the past 90 days.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.52% of the outstanding shares of Dr. Reddy's Laboratories have been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently increased by 15.57%, indicating that investor sentiment is decreasing significantly. Previous Next 1.7 Dividend Strength Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.59%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories has only been increasing its dividend for 4 years.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 10.17%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.10% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RDY. Previous Next 1.1 News and Social Media Coverage News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 3 people have added Dr. Reddy's Laboratories to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by InstitutionsOnly 14.02% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to decrease by -0.73% in the coming year, from $4.09 to $4.06 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 16.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.82.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 16.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.53.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 1.53. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 3.36. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dr. Reddy's Laboratories' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About Dr. Reddy's Laboratories Stock (NYSE:RDY)Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.Read More RDY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RDY Stock News HeadlinesMay 16 at 3:26 AM | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) Downgraded to "Buy" at StockNews.comMay 10, 2024 | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) PT Raised to $81.00 at BarclaysMay 10, 2024 | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) Rating Increased to Strong-Buy at StockNews.comMay 8, 2024 | finance.yahoo.comDr. Reddy’s Laboratories Limited (NYSE:RDY) Q4 2024 Earnings Call TranscriptMay 7, 2024 | finance.yahoo.comDr. Reddy’s Q4 & Full Year FY24 Financial ResultsMay 7, 2024 | businesswire.comDr. Reddy's Q4 & Full Year FY24 Financial ResultsMay 7, 2024 | reuters.comIndia's Dr Reddy's beats Q4 profit estimatesMay 7, 2024 | markets.businessinsider.comHere's what Wall Street expects from Dr Reddys Laboratories's earnings reportMay 7, 2024 | sg.finance.yahoo.comIndia's Dr Reddy's beats Q4 profit view; names new CFOMay 3, 2024 | businesswire.comDr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.April 23, 2024 | usatoday.comDr. Reddy’s Issues Voluntary Nationwide Recall of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg Due to Sub-PotencyMarch 22, 2024 | finance.yahoo.comPharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in IndiaMarch 19, 2024 | businesswire.comDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UKFebruary 24, 2024 | msn.comDr. Reddy's Laboratories Limited - Depositary Receipt () (RDY) Price Target Increased by 5.17% to 71.72February 22, 2024 | msn.comGlobal Access to Weight-Loss Treatments: Indian Pharma Giants Eye Affordable Wegovy Alternatives Amid Rising DemandFebruary 22, 2024 | msn.comNovo to face Wegovy competition in India as local versions loom: ReutersFebruary 6, 2024 | ca.finance.yahoo.comRDY Jun 2024 60.000 callFebruary 1, 2024 | finance.yahoo.comDr. Reddy's (RDY) Q3 Earnings and Revenues Surpass EstimatesFebruary 1, 2024 | finance.yahoo.comDr. Reddy’s Laboratories Limited (NYSE:RDY) Q3 2024 Earnings Call TranscriptJanuary 31, 2024 | msn.comTeva hits 52-week high on outlook, API divestmentJanuary 31, 2024 | finance.yahoo.comUPDATE 1-Indian pharma firm Dr Reddy's beats Q3 profit view on strong US, European businessesJanuary 31, 2024 | finance.yahoo.comDr. Reddy’s Q3 & 9M FY24 Financial ResultsJanuary 17, 2024 | msn.comIndian pharma group Dr Reddy's eyes swoop on NicotinellJanuary 11, 2024 | realmoney.thestreet.comDr. Reddy's just downgraded at Jefferies, here's whyDecember 29, 2023 | msn.comDr. Reddy's acquires 6.46% stake in Israeli biotech Edity TherapeuticsSee More Headlines Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings1/31/2024Today5/17/2024Next Earnings (Estimated)7/24/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:RDY CUSIPN/A CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees25,863Year Founded1984Price Target and Rating Average Stock Price Target$81.00 High Stock Price Target$81.00 Low Stock Price Target$81.00 Potential Upside/Downside+18.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$4.03 Trailing P/E Ratio16.94 Forward P/E Ratio16.69 P/E Growth1.54Net Income$673.78 million Net Margins19.97% Pretax Margin25.75% Return on Equity21.27% Return on Assets15.44% Debt Debt-to-Equity Ratio0.02 Current Ratio2.58 Quick Ratio1.92 Sales & Book Value Annual Sales$3.35 billion Price / Sales3.40 Cash Flow$4.98 per share Price / Cash Flow13.71 Book Value$20.34 per share Price / Book3.36Miscellaneous Outstanding Shares166,880,000Free Float163,540,000Market Cap$11.39 billion OptionableOptionable Beta0.57 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Gunupati Venkateswara Prasad B.E. (Age 64)Co-Chairman, MD & Member of Management Council Comp: $2.25MMr. Kallam Satish Reddy B.Tech. (Age 57)M.S., Chairman of the Board & Member of the Management Council Comp: $1.38MMr. Erez Israeli M.B.A. (Age 56)CEO & Member of the Management Council Mr. Parag Agarwal (Age 57)CFO & Member of Management Council Mr. Deepak Sapra M.B.A. (Age 49)CEO of API & Services & Member of Management Council Mr. Venkata Ramana Motupalli M.B.A. (Age 55)CEO of Branded Markets - India & Emerging Countries and Member of Management Council Ms. Archana Bhaskar B.Sc. (Age 57)M.B.A., EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management Council Mr. Sanjay Sharma B.Tech. (Age 56)Executive VP, Global Head of Global Manufacturing & Member of Management Council Mr. Marc Kikuchi B.A. (Age 55)M.B.A., CEO of North America Generics & Member of Management Council Mr. Patrick Aghanian B.A. (Age 59)M.B.A., CEO of European Generics & Member of Management Council More ExecutivesKey CompetitorsUnited TherapeuticsNASDAQ:UTHRSarepta TherapeuticsNASDAQ:SRPTCatalentNYSE:CTLTViatrisNASDAQ:VTRSRoivant SciencesNASDAQ:ROIVView All CompetitorsInstitutional OwnershipWalleye Trading LLCBought 4,800 shares on 5/17/2024Ownership: 0.000%Jane Street Group LLCBought 108,243 shares on 5/16/2024Ownership: 0.068%Bellevue Group AGSold 20,004 shares on 5/15/2024Ownership: 0.025%SVB Wealth LLCSold 1,599 shares on 5/15/2024Ownership: 0.002%OLD Mission Capital LLCBought 18,930 shares on 5/14/2024Ownership: 0.028%View All Institutional Transactions RDY Stock Analysis - Frequently Asked Questions Should I buy or sell Dr. Reddy's Laboratories stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dr. Reddy's Laboratories in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" RDY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RDY, but not buy additional shares or sell existing shares. View RDY analyst ratings or view top-rated stocks. What is Dr. Reddy's Laboratories' stock price target for 2024? 3 Wall Street analysts have issued twelve-month price objectives for Dr. Reddy's Laboratories' shares. Their RDY share price targets range from $81.00 to $81.00. On average, they predict the company's stock price to reach $81.00 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View analysts price targets for RDY or view top-rated stocks among Wall Street analysts. How have RDY shares performed in 2024? Dr. Reddy's Laboratories' stock was trading at $69.58 at the beginning of 2024. Since then, RDY stock has decreased by 1.9% and is now trading at $68.25. View the best growth stocks for 2024 here. Are investors shorting Dr. Reddy's Laboratories? Dr. Reddy's Laboratories saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 751,000 shares, an increase of 20.0% from the March 31st total of 625,800 shares. Based on an average daily volume of 193,400 shares, the short-interest ratio is presently 3.9 days. View Dr. Reddy's Laboratories' Short Interest. When is Dr. Reddy's Laboratories' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 24th 2024. View our RDY earnings forecast. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Limited (NYSE:RDY) released its quarterly earnings results on Wednesday, January, 31st. The company reported $0.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.11. The company had revenue of $867 million for the quarter, compared to analysts' expectations of $827.81 million. Dr. Reddy's Laboratories had a net margin of 19.97% and a trailing twelve-month return on equity of 21.27%. How often does Dr. Reddy's Laboratories pay dividends? What is the dividend yield for Dr. Reddy's Laboratories? Dr. Reddy's Laboratories announced an annual dividend on Tuesday, July 18th. Shareholders of record on Friday, January 1st will be paid a dividend of $0.4877 per share on Friday, July 28th. This represents a yield of 0.7%. The ex-dividend date is Friday, July 28th. This is a positive change from the stock's previous annual dividend of $0.33. Read our dividend analysis for RDY. Is Dr. Reddy's Laboratories a good dividend stock? Dr. Reddy's Laboratories (NYSE:RDY) pays an annual dividend of $0.41 per share and currently has a dividend yield of 0.59%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 10.17%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, RDY will have a dividend payout ratio of 10.10% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for RDY. What ETFs hold Dr. Reddy's Laboratories' stock? ETFs with the largest weight of Dr. Reddy's Laboratories (NYSE:RDY) stock in their portfolio include Putnam PanAgora ESG Emerging Markets Equity ETF (PPEM), First Trust BICK Index Fund (BICK), ALPS Emerging Sector Dividend Dogs ETF (EDOG), Hartford Multifactor Diversified International ETF (RODE) and Avantis Emerging Markets ex-China Equity ETF (AVXC).SPDR Bloomberg SASB Emerging Markets ESG Select ETF (REMG). What is G. V. Prasad's approval rating as Dr. Reddy's Laboratories' CEO? 528 employees have rated Dr. Reddy's Laboratories Chief Executive Officer G. V. Prasad on Glassdoor.com. G. V. Prasad has an approval rating of 96% among the company's employees. This puts G. V. Prasad in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dr. Reddy's Laboratories investors own include Siemens Aktiengesellschaft (SIEGY), Tata Motors (TTM), Infosys (INFY), HDFC Bank (HDB), Alibaba Group (BABA), GSK (GSK), Merck & Co., Inc. (MRK), NVIDIA (NVDA) and Pfizer (PFE). Who are Dr. Reddy's Laboratories' major shareholders? Dr. Reddy's Laboratories' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.61%), Acadian Asset Management LLC (0.12%), Mondrian Investment Partners LTD (0.10%), Assenagon Asset Management S.A. (0.10%), Promethos Capital LLC (0.07%) and Jane Street Group LLC (0.07%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:RDY) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.